---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-011441"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2025-07-28T23:59:59+00:00"
generated_at: "2026-05-18T00:46:33.575886+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AIM ImmunoTech reports positive mid-year Phase 2 data for Ampligen+Imfinzi in pancreatic cancer

## Summary
- No grade ≥2 immune-related or systemic toxicities reported across 14 enrolled patients.
- 3 of 14 patients (21%) had PFS >6 months; 3 additional patients not yet progressed at cutoff.
- Of 11 evaluable patients, 7 (64%) achieved overall survival >6 months.
- Combination of Ampligen (rintatolimod) and AstraZeneca's Imfinzi (durvalumab) studied post-FOLFIRINOX.
- Final analysis pending immune-monitoring data from paired biopsies and blood samples.

## SEC filing metadata
- accession: 0001493152-25-011441
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2025-07-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315225011441/0001493152-25-011441-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315225011441/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-011441
- JSON: https://secwatch.observer/filing/0001493152-25-011441.json
- Plain text: https://secwatch.observer/filing/0001493152-25-011441.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.